SCHEMBL20239233

SCHEMBL20239233

CS(=O)(=O)NCCc1ccc(Oc2cc(Cl)nc(Cl)n2)cc1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.53
RAB9A P51151 1/20 0.53
SMN1; SMN2 Q16637 2/20 0.49
KMT2A Q03164 2/20 0.42
MEN1 O00255 1/20 0.42
CA12 O43570 2/20 0.41
CA1 P00915 2/20 0.41
CA2 P00918 2/20 0.41
CA9 Q16790 2/20 0.41
CA14 Q9ULX7 2/20 0.41
CA5A P35218 1/20 0.41
PLAAT3 P53816 1/20 0.39
PLAAT5 Q96KN8 1/20 0.39
PLAAT2 Q9NWW9 1/20 0.39
PLAAT4 Q9UL19 1/20 0.39
POLB P06746 1/20 0.38
GRIA4 P48058 1/20 0.37
KCNH2 Q12809 1/20 0.36
CYP3A4 P08684 1/20 0.36
MTNR1A P48039 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20239253 0.87 ALDH1A1 (0.43) ALDH1A1RAB9ASMN1; SMN2CA12CA1
SCHEMBL20259163 0.82 ALDH1A1 (0.46) ALDH1A1RAB9ASMN1; SMN2KMT2ACA12
SCHEMBL21924535 0.80 ALDH1A1 (0.43) ALDH1A1RAB9ASMN1; SMN2KMT2ACA12
SCHEMBL18249751 0.79 PGR (0.54) ALDH1A1RAB9ASMN1; SMN2KMT2AMEN1
SCHEMBL18249752 0.75 SMN1; SMN2 (0.51) ALDH1A1RAB9ASMN1; SMN2KMT2AMEN1
SCHEMBL20239226 0.74 DGAT2 (0.53) ALDH1A1RAB9ASMN1; SMN2KMT2AMEN1
SCHEMBL2093102 0.72 CA12 (0.73) ALDH1A1SMN1; SMN2CA12CA1CA2
SCHEMBL20239137 0.72 SMN1; SMN2 (0.46) ALDH1A1SMN1; SMN2CA12CA1CA2
SCHEMBL20239243 0.72 DGAT2 (0.42) ALDH1A1RAB9APLAAT3PLAAT5PLAAT2
SCHEMBL1267234 0.71 MEN1 (0.57) ALDH1A1KMT2AMEN1CA12CA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-107635975-B DGAT2 inhibitors 伊莱利利公司 2020-07-24 CN disclosed
EP-3298001-B1 DGAT2 INHIBITORS LILLY CO ELI (US) 2020-05-13 EP disclosed
US-10053429-B2 DGAT2 inhibitors ELI LILLY AND COMPANY (US) 2018-08-21 US disclosed
US-20180162825-A1 NOVEL DGAT2 INHIBITORS ELI LILY AND COMPANY (US) 2018-06-14 US disclosed
US-20180162825-A1 NOVEL DGAT2 INHIBITORS ELI LILY AND COMPANY (US) 2018-06-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180162825-A1 NOVEL DGAT2 INHIBITORS DGAT2, DGAT1, LCAT ALDH1A1 1430/4885RAB9A 1170/4885SMN1; SMN2 4828/4885
US-10053429-B2 DGAT2 inhibitors DGAT2, DGAT1, LCAT ALDH1A1 1189/4885RAB9A 1119/4885SMN1; SMN2 4835/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.